STOCK TITAN

[8-K] American Woodmark Corp Reports Material Event

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Charles River Laboratories (CRL) Q2-25 10-Q highlights: Revenue was essentially flat at $1.03 bn (+0.6% YoY). Service revenue slipped 0.2% to $840.8 mn while product revenue rose 4.4% to $191.3 mn.

Profitability compressed sharply. Operating income dropped 34% to $100.1 mn as amortization of intangibles more than doubled (to $65.4 mn) due to accelerated write-offs of CDMO client relationships. Net income attributable to CRL fell 44% to $52.3 mn; diluted EPS declined to $1.06 from $1.74.

Segment trends:

  • RMS: revenue +3.3% to $213.3 mn; operating margin expanded to 16.8% (+180 bp).
  • DSA: revenue -1.5% to $618.0 mn; operating margin contracted 160 bp to 19.9%.
  • Manufacturing: revenue +4.4% to $200.8 mn but operating income collapsed 68% to $12.1 mn, mainly from higher amortization.

Cash & capital: Operating cash flow strengthened to $376.3 mn (+16% YoY) while capex fell 20% to $94.6 mn, yielding improved free cash flow. The company repurchased $360.5 mn of shares (2.1 mn shares) and now has $549.3 mn remaining under its $1 bn authorization. Cash stood at $182.8 mn and gross debt at $2.35 bn; net leverage ticked up.

Balance sheet changes: Goodwill rose $89 mn on FX; intangibles fell $121 mn from accelerated amortization. Treasury stock of $363.3 mn reflects recent buybacks.

Other items: Effective tax rate rose to 26.2% (vs. 21.2%). Restructuring charges totaled $32.2 mn in the quarter. Management flags supply-chain, SEC investigation into NHP sourcing, and multiple lawsuits as continuing uncertainties.

Charles River Laboratories (CRL) Q2-25 10-Q punti salienti: Il fatturato è rimasto praticamente stabile a 1,03 miliardi di dollari (+0,6% su base annua). I ricavi da servizi sono leggermente diminuiti dello 0,2% a 840,8 milioni di dollari, mentre i ricavi da prodotti sono aumentati del 4,4% a 191,3 milioni di dollari.

La redditività si è fortemente ridotta. L'utile operativo è calato del 34% a 100,1 milioni di dollari, a causa del raddoppio dell'ammortamento degli intangibili (65,4 milioni di dollari) dovuto a una più rapida svalutazione delle relazioni con i clienti CDMO. L'utile netto attribuibile a CRL è sceso del 44% a 52,3 milioni di dollari; l'EPS diluito è diminuito da 1,74 a 1,06 dollari.

Tendenze per segmento:

  • RMS: ricavi +3,3% a 213,3 milioni di dollari; margine operativo aumentato al 16,8% (+180 punti base).
  • DSA: ricavi -1,5% a 618,0 milioni di dollari; margine operativo ridotto di 160 punti base al 19,9%.
  • Produzione: ricavi +4,4% a 200,8 milioni di dollari, ma utile operativo crollato del 68% a 12,1 milioni di dollari, principalmente per l’aumento dell’ammortamento.

Liquidità e capitale: Il flusso di cassa operativo è aumentato a 376,3 milioni di dollari (+16% su base annua), mentre gli investimenti in capitale sono diminuiti del 20% a 94,6 milioni di dollari, migliorando il flusso di cassa libero. La società ha riacquistato azioni per 360,5 milioni di dollari (2,1 milioni di azioni) e dispone ancora di 549,3 milioni di dollari sotto l’autorizzazione da 1 miliardo. La liquidità disponibile era di 182,8 milioni di dollari, il debito lordo a 2,35 miliardi; la leva finanziaria netta è leggermente aumentata.

Variazioni di bilancio: L’avviamento è aumentato di 89 milioni di dollari per variazioni valutarie; gli intangibili sono diminuiti di 121 milioni per ammortamenti accelerati. Le azioni proprie in portafoglio ammontano a 363,3 milioni, riflettendo i recenti buyback.

Altri elementi: L’aliquota fiscale effettiva è salita al 26,2% (dal 21,2%). Le spese di ristrutturazione nel trimestre sono state di 32,2 milioni di dollari. La direzione segnala come incertezze persistenti la catena di approvvigionamento, l’indagine SEC sull’origine degli NHP e numerose cause legali.

Aspectos destacados del 10-Q del Q2-25 de Charles River Laboratories (CRL): Los ingresos se mantuvieron prácticamente estables en 1.03 mil millones de dólares (+0.6% interanual). Los ingresos por servicios disminuyeron un 0.2% a 840.8 millones, mientras que los ingresos por productos aumentaron un 4.4% a 191.3 millones de dólares.

La rentabilidad se comprimió drásticamente. El ingreso operativo cayó un 34% a 100.1 millones debido a que la amortización de intangibles más que se duplicó (a 65.4 millones) por la aceleración de las bajas contables relacionadas con clientes CDMO. El ingreso neto atribuible a CRL bajó un 44% a 52.3 millones; las ganancias por acción diluidas disminuyeron de 1.74 a 1.06 dólares.

Tendencias por segmento:

  • RMS: ingresos +3.3% a 213.3 millones; margen operativo aumentó a 16.8% (+180 pb).
  • DSA: ingresos -1.5% a 618.0 millones; margen operativo se redujo 160 pb a 19.9%.
  • Manufactura: ingresos +4.4% a 200.8 millones, pero ingreso operativo se desplomó 68% a 12.1 millones, principalmente por mayor amortización.

Flujo de caja y capital: El flujo de caja operativo aumentó a 376.3 millones (+16% interanual), mientras que el gasto de capital cayó 20% a 94.6 millones, mejorando el flujo de caja libre. La compañía recompró acciones por 360.5 millones (2.1 millones de acciones) y aún tiene 549.3 millones disponibles bajo su autorización de 1 mil millones. El efectivo era de 182.8 millones y la deuda bruta de 2.35 mil millones; el apalancamiento neto subió ligeramente.

Cambios en el balance: El goodwill aumentó 89 millones por efectos cambiarios; los intangibles disminuyeron 121 millones por amortización acelerada. Las acciones en tesorería suman 363.3 millones, reflejando recompras recientes.

Otros aspectos: La tasa impositiva efectiva subió a 26.2% (vs. 21.2%). Los cargos por reestructuración totalizaron 32.2 millones en el trimestre. La dirección señala la cadena de suministro, la investigación de la SEC sobre el origen de NHP, y múltiples demandas como incertidumbres continuas.

Charles River Laboratories (CRL) 2025년 2분기 10-Q 주요 내용: 매출은 전년 대비 0.6% 증가한 10억 3천만 달러로 거의 변동이 없었습니다. 서비스 매출은 0.2% 감소한 8억 4,080만 달러였고, 제품 매출은 4.4% 증가한 1억 9,130만 달러를 기록했습니다.

수익성이 크게 악화되었습니다. 무형자산 상각비가 두 배 이상 증가(6,540만 달러)하여 CDMO 고객 관계에 대한 조기 상각이 반영되면서 영업이익은 34% 감소한 1억 10만 달러가 되었습니다. CRL 귀속 순이익은 44% 감소한 5,230만 달러였으며, 희석 주당순이익(EPS)은 1.74달러에서 1.06달러로 하락했습니다.

사업 부문별 동향:

  • RMS: 매출 3.3% 증가한 2억 1,330만 달러; 영업이익률은 16.8%로 180bp 상승.
  • DSA: 매출 1.5% 감소한 6억 1,800만 달러; 영업이익률은 19.9%로 160bp 하락.
  • 제조 부문: 매출 4.4% 증가한 2억 800만 달러, 그러나 상각비 증가로 영업이익은 68% 급감한 1,210만 달러.

현금 및 자본 상황: 영업현금흐름은 16% 증가한 3억 7,630만 달러로 강화되었으며, 자본적 지출은 20% 감소한 9,460만 달러로 자유현금흐름이 개선되었습니다. 회사는 3억 6,050만 달러(210만 주) 규모의 자사주를 매입했으며, 10억 달러 한도 내에서 5억 4,930만 달러가 남아 있습니다. 현금은 1억 8,280만 달러, 총 부채는 23억 5천만 달러였으며, 순차입금 비율은 소폭 상승했습니다.

대차대조표 변동: 환율 변동으로 영업권이 8,900만 달러 증가했고, 무형자산은 조기 상각으로 1억 2,100만 달러 감소했습니다. 최근 자사주 매입으로 인해 자사주 가치는 3억 6,330만 달러입니다.

기타 사항: 유효 세율은 21.2%에서 26.2%로 상승했습니다. 분기 중 구조조정 비용은 3,220만 달러에 달했습니다. 경영진은 공급망 문제, NHP 출처에 관한 SEC 조사, 다수의 소송을 지속적인 불확실성으로 지적하고 있습니다.

Points clés du 10-Q T2-25 de Charles River Laboratories (CRL) : Le chiffre d'affaires est resté quasi stable à 1,03 milliard de dollars (+0,6% en glissement annuel). Les revenus de services ont légèrement reculé de 0,2% à 840,8 millions de dollars, tandis que les revenus produits ont augmenté de 4,4% à 191,3 millions de dollars.

La rentabilité s’est nettement contractée. Le résultat opérationnel a chuté de 34% à 100,1 millions de dollars, l’amortissement des actifs incorporels ayant plus que doublé (à 65,4 millions) en raison d’une dépréciation accélérée des relations clients CDMO. Le résultat net attribuable à CRL a diminué de 44% à 52,3 millions ; le BPA dilué est passé de 1,74 à 1,06 dollar.

Tendances par segment :

  • RMS : chiffre d’affaires en hausse de 3,3% à 213,3 millions ; marge opérationnelle portée à 16,8% (+180 points de base).
  • DSA : chiffre d’affaires en baisse de 1,5% à 618,0 millions ; marge opérationnelle réduite de 160 points de base à 19,9%.
  • Fabrication : chiffre d’affaires en hausse de 4,4% à 200,8 millions, mais résultat opérationnel en chute de 68% à 12,1 millions, principalement à cause d’une amortissement plus élevé.

Trésorerie et capital : Les flux de trésorerie opérationnels ont augmenté de 16% à 376,3 millions, tandis que les dépenses d’investissement ont diminué de 20% à 94,6 millions, améliorant le flux de trésorerie disponible. La société a racheté pour 360,5 millions d’actions (2,1 millions d’actions) et dispose encore de 549,3 millions sous son autorisation d’un milliard. La trésorerie s’élève à 182,8 millions et la dette brute à 2,35 milliards ; l’endettement net a légèrement augmenté.

Évolutions du bilan : Le goodwill a augmenté de 89 millions en raison des variations de change ; les actifs incorporels ont diminué de 121 millions suite à des amortissements accélérés. Le stock d’actions propres de 363,3 millions reflète les rachats récents.

Autres éléments : Le taux d’imposition effectif est passé à 26,2% (contre 21,2%). Les charges de restructuration ont totalisé 32,2 millions au trimestre. La direction signale comme incertitudes persistantes la chaîne d’approvisionnement, l’enquête de la SEC sur l’origine des NHP et plusieurs poursuites judiciaires.

Charles River Laboratories (CRL) Q2-25 10-Q Highlights: Der Umsatz blieb mit 1,03 Mrd. USD im Wesentlichen stabil (+0,6% im Jahresvergleich). Die Serviceerlöse sanken leicht um 0,2% auf 840,8 Mio. USD, während die Produktumsätze um 4,4% auf 191,3 Mio. USD stiegen.

Die Profitabilität ging deutlich zurück. Das operative Ergebnis sank um 34% auf 100,1 Mio. USD, da die Abschreibungen auf immaterielle Vermögenswerte aufgrund beschleunigter Abschreibungen von CDMO-Kundenbeziehungen mehr als verdoppelt wurden (auf 65,4 Mio. USD). Der dem Unternehmen zurechenbare Nettogewinn fiel um 44% auf 52,3 Mio. USD; das verwässerte Ergebnis je Aktie sank von 1,74 auf 1,06 USD.

Segmenttrends:

  • RMS: Umsatz +3,3% auf 213,3 Mio. USD; operative Marge stieg auf 16,8% (+180 Basispunkte).
  • DSA: Umsatz -1,5% auf 618,0 Mio. USD; operative Marge sank um 160 Basispunkte auf 19,9%.
  • Fertigung: Umsatz +4,4% auf 200,8 Mio. USD, aber operatives Ergebnis brach um 68% auf 12,1 Mio. USD ein, hauptsächlich aufgrund höherer Abschreibungen.

Barmittel & Kapital: Der operative Cashflow stieg um 16% auf 376,3 Mio. USD, während die Investitionsausgaben um 20% auf 94,6 Mio. USD zurückgingen, was den freien Cashflow verbesserte. Das Unternehmen kaufte Aktien im Wert von 360,5 Mio. USD (2,1 Mio. Aktien) zurück und verfügt noch über 549,3 Mio. USD unter seiner 1-Milliarde-USD-Autorisierung. Die liquiden Mittel betrugen 182,8 Mio. USD, die Bruttoverschuldung 2,35 Mrd. USD; die Nettoverschuldung stieg leicht an.

Bilanzveränderungen: Der Firmenwert stieg um 89 Mio. USD aufgrund von Wechselkurseffekten; immaterielle Vermögenswerte sanken um 121 Mio. USD durch beschleunigte Abschreibungen. Eigene Aktien im Wert von 363,3 Mio. USD spiegeln die jüngsten Rückkäufe wider.

Sonstige Punkte: Der effektive Steuersatz stieg auf 26,2% (von 21,2%). Restrukturierungskosten beliefen sich im Quartal auf 32,2 Mio. USD. Das Management weist auf weiterhin bestehende Unsicherheiten hin, darunter Lieferkettenprobleme, eine SEC-Untersuchung zur NHP-Beschaffung und mehrere Rechtsstreitigkeiten.

Positive
  • Operating cash flow grew 16% YoY to $376 mn, boosting free cash flow despite profit decline.
  • RMS segment delivered 3.3% revenue growth and margin expansion, indicating steady model demand.
  • Share repurchases of 2.1 mn shares signal confidence and provide EPS support; $549 mn authorization remains.
  • Capex discipline (-20% YoY) helps preserve liquidity.
Negative
  • Net income fell 44% YoY; diluted EPS down to $1.06 from $1.74.
  • Operating margin contracted 510 bp to 9.7% due to doubled amortization and higher SG&A.
  • Manufacturing segment operating income collapsed 68%, reflecting CDMO customer losses.
  • Leverage increased as debt rose to finance buybacks; net cash declined $12 mn since YE.
  • Regulatory & legal overhang: SEC NHP investigation and multiple lawsuits remain unresolved.

Insights

TL;DR – Flat revenue but margins crater; cash flow solid; watch elevated amortization & litigation risk.

Revenue stability masks significant profit erosion driven by a 103% jump in intangible amortization and higher SG&A. Manufacturing’s 480 bp margin compression is particularly concerning, signaling continued CDMO weakness. Cash flow performance and disciplined capex temper the blow, yet leverage has crept higher as buybacks outstrip earnings. Litigation (SEC NHP probe, class-action, derivatives) remains an overhang and could limit multiple expansion. Guidance was not reiterated in the filing; investors should expect consensus EPS downgrades.

TL;DR – Core demand steady; restructuring & amortization are transitory, offering a long entry for patient holders.

The flat top-line and resilient RMS growth suggest end-market demand is intact despite biotech funding pressures. Accelerated amortization is non-cash and front-loads CDMO pain, potentially clearing the deck for FY-26 margin recovery. Operating cash flow covers capex and a sizable portion of buybacks, indicating balance-sheet flexibility. However, with leverage >2.5× EBITDA and regulatory uncertainty, position sizing is key. A re-rating hinges on DSA margin stabilization and resolution of NHP supply issues.

Charles River Laboratories (CRL) Q2-25 10-Q punti salienti: Il fatturato è rimasto praticamente stabile a 1,03 miliardi di dollari (+0,6% su base annua). I ricavi da servizi sono leggermente diminuiti dello 0,2% a 840,8 milioni di dollari, mentre i ricavi da prodotti sono aumentati del 4,4% a 191,3 milioni di dollari.

La redditività si è fortemente ridotta. L'utile operativo è calato del 34% a 100,1 milioni di dollari, a causa del raddoppio dell'ammortamento degli intangibili (65,4 milioni di dollari) dovuto a una più rapida svalutazione delle relazioni con i clienti CDMO. L'utile netto attribuibile a CRL è sceso del 44% a 52,3 milioni di dollari; l'EPS diluito è diminuito da 1,74 a 1,06 dollari.

Tendenze per segmento:

  • RMS: ricavi +3,3% a 213,3 milioni di dollari; margine operativo aumentato al 16,8% (+180 punti base).
  • DSA: ricavi -1,5% a 618,0 milioni di dollari; margine operativo ridotto di 160 punti base al 19,9%.
  • Produzione: ricavi +4,4% a 200,8 milioni di dollari, ma utile operativo crollato del 68% a 12,1 milioni di dollari, principalmente per l’aumento dell’ammortamento.

Liquidità e capitale: Il flusso di cassa operativo è aumentato a 376,3 milioni di dollari (+16% su base annua), mentre gli investimenti in capitale sono diminuiti del 20% a 94,6 milioni di dollari, migliorando il flusso di cassa libero. La società ha riacquistato azioni per 360,5 milioni di dollari (2,1 milioni di azioni) e dispone ancora di 549,3 milioni di dollari sotto l’autorizzazione da 1 miliardo. La liquidità disponibile era di 182,8 milioni di dollari, il debito lordo a 2,35 miliardi; la leva finanziaria netta è leggermente aumentata.

Variazioni di bilancio: L’avviamento è aumentato di 89 milioni di dollari per variazioni valutarie; gli intangibili sono diminuiti di 121 milioni per ammortamenti accelerati. Le azioni proprie in portafoglio ammontano a 363,3 milioni, riflettendo i recenti buyback.

Altri elementi: L’aliquota fiscale effettiva è salita al 26,2% (dal 21,2%). Le spese di ristrutturazione nel trimestre sono state di 32,2 milioni di dollari. La direzione segnala come incertezze persistenti la catena di approvvigionamento, l’indagine SEC sull’origine degli NHP e numerose cause legali.

Aspectos destacados del 10-Q del Q2-25 de Charles River Laboratories (CRL): Los ingresos se mantuvieron prácticamente estables en 1.03 mil millones de dólares (+0.6% interanual). Los ingresos por servicios disminuyeron un 0.2% a 840.8 millones, mientras que los ingresos por productos aumentaron un 4.4% a 191.3 millones de dólares.

La rentabilidad se comprimió drásticamente. El ingreso operativo cayó un 34% a 100.1 millones debido a que la amortización de intangibles más que se duplicó (a 65.4 millones) por la aceleración de las bajas contables relacionadas con clientes CDMO. El ingreso neto atribuible a CRL bajó un 44% a 52.3 millones; las ganancias por acción diluidas disminuyeron de 1.74 a 1.06 dólares.

Tendencias por segmento:

  • RMS: ingresos +3.3% a 213.3 millones; margen operativo aumentó a 16.8% (+180 pb).
  • DSA: ingresos -1.5% a 618.0 millones; margen operativo se redujo 160 pb a 19.9%.
  • Manufactura: ingresos +4.4% a 200.8 millones, pero ingreso operativo se desplomó 68% a 12.1 millones, principalmente por mayor amortización.

Flujo de caja y capital: El flujo de caja operativo aumentó a 376.3 millones (+16% interanual), mientras que el gasto de capital cayó 20% a 94.6 millones, mejorando el flujo de caja libre. La compañía recompró acciones por 360.5 millones (2.1 millones de acciones) y aún tiene 549.3 millones disponibles bajo su autorización de 1 mil millones. El efectivo era de 182.8 millones y la deuda bruta de 2.35 mil millones; el apalancamiento neto subió ligeramente.

Cambios en el balance: El goodwill aumentó 89 millones por efectos cambiarios; los intangibles disminuyeron 121 millones por amortización acelerada. Las acciones en tesorería suman 363.3 millones, reflejando recompras recientes.

Otros aspectos: La tasa impositiva efectiva subió a 26.2% (vs. 21.2%). Los cargos por reestructuración totalizaron 32.2 millones en el trimestre. La dirección señala la cadena de suministro, la investigación de la SEC sobre el origen de NHP, y múltiples demandas como incertidumbres continuas.

Charles River Laboratories (CRL) 2025년 2분기 10-Q 주요 내용: 매출은 전년 대비 0.6% 증가한 10억 3천만 달러로 거의 변동이 없었습니다. 서비스 매출은 0.2% 감소한 8억 4,080만 달러였고, 제품 매출은 4.4% 증가한 1억 9,130만 달러를 기록했습니다.

수익성이 크게 악화되었습니다. 무형자산 상각비가 두 배 이상 증가(6,540만 달러)하여 CDMO 고객 관계에 대한 조기 상각이 반영되면서 영업이익은 34% 감소한 1억 10만 달러가 되었습니다. CRL 귀속 순이익은 44% 감소한 5,230만 달러였으며, 희석 주당순이익(EPS)은 1.74달러에서 1.06달러로 하락했습니다.

사업 부문별 동향:

  • RMS: 매출 3.3% 증가한 2억 1,330만 달러; 영업이익률은 16.8%로 180bp 상승.
  • DSA: 매출 1.5% 감소한 6억 1,800만 달러; 영업이익률은 19.9%로 160bp 하락.
  • 제조 부문: 매출 4.4% 증가한 2억 800만 달러, 그러나 상각비 증가로 영업이익은 68% 급감한 1,210만 달러.

현금 및 자본 상황: 영업현금흐름은 16% 증가한 3억 7,630만 달러로 강화되었으며, 자본적 지출은 20% 감소한 9,460만 달러로 자유현금흐름이 개선되었습니다. 회사는 3억 6,050만 달러(210만 주) 규모의 자사주를 매입했으며, 10억 달러 한도 내에서 5억 4,930만 달러가 남아 있습니다. 현금은 1억 8,280만 달러, 총 부채는 23억 5천만 달러였으며, 순차입금 비율은 소폭 상승했습니다.

대차대조표 변동: 환율 변동으로 영업권이 8,900만 달러 증가했고, 무형자산은 조기 상각으로 1억 2,100만 달러 감소했습니다. 최근 자사주 매입으로 인해 자사주 가치는 3억 6,330만 달러입니다.

기타 사항: 유효 세율은 21.2%에서 26.2%로 상승했습니다. 분기 중 구조조정 비용은 3,220만 달러에 달했습니다. 경영진은 공급망 문제, NHP 출처에 관한 SEC 조사, 다수의 소송을 지속적인 불확실성으로 지적하고 있습니다.

Points clés du 10-Q T2-25 de Charles River Laboratories (CRL) : Le chiffre d'affaires est resté quasi stable à 1,03 milliard de dollars (+0,6% en glissement annuel). Les revenus de services ont légèrement reculé de 0,2% à 840,8 millions de dollars, tandis que les revenus produits ont augmenté de 4,4% à 191,3 millions de dollars.

La rentabilité s’est nettement contractée. Le résultat opérationnel a chuté de 34% à 100,1 millions de dollars, l’amortissement des actifs incorporels ayant plus que doublé (à 65,4 millions) en raison d’une dépréciation accélérée des relations clients CDMO. Le résultat net attribuable à CRL a diminué de 44% à 52,3 millions ; le BPA dilué est passé de 1,74 à 1,06 dollar.

Tendances par segment :

  • RMS : chiffre d’affaires en hausse de 3,3% à 213,3 millions ; marge opérationnelle portée à 16,8% (+180 points de base).
  • DSA : chiffre d’affaires en baisse de 1,5% à 618,0 millions ; marge opérationnelle réduite de 160 points de base à 19,9%.
  • Fabrication : chiffre d’affaires en hausse de 4,4% à 200,8 millions, mais résultat opérationnel en chute de 68% à 12,1 millions, principalement à cause d’une amortissement plus élevé.

Trésorerie et capital : Les flux de trésorerie opérationnels ont augmenté de 16% à 376,3 millions, tandis que les dépenses d’investissement ont diminué de 20% à 94,6 millions, améliorant le flux de trésorerie disponible. La société a racheté pour 360,5 millions d’actions (2,1 millions d’actions) et dispose encore de 549,3 millions sous son autorisation d’un milliard. La trésorerie s’élève à 182,8 millions et la dette brute à 2,35 milliards ; l’endettement net a légèrement augmenté.

Évolutions du bilan : Le goodwill a augmenté de 89 millions en raison des variations de change ; les actifs incorporels ont diminué de 121 millions suite à des amortissements accélérés. Le stock d’actions propres de 363,3 millions reflète les rachats récents.

Autres éléments : Le taux d’imposition effectif est passé à 26,2% (contre 21,2%). Les charges de restructuration ont totalisé 32,2 millions au trimestre. La direction signale comme incertitudes persistantes la chaîne d’approvisionnement, l’enquête de la SEC sur l’origine des NHP et plusieurs poursuites judiciaires.

Charles River Laboratories (CRL) Q2-25 10-Q Highlights: Der Umsatz blieb mit 1,03 Mrd. USD im Wesentlichen stabil (+0,6% im Jahresvergleich). Die Serviceerlöse sanken leicht um 0,2% auf 840,8 Mio. USD, während die Produktumsätze um 4,4% auf 191,3 Mio. USD stiegen.

Die Profitabilität ging deutlich zurück. Das operative Ergebnis sank um 34% auf 100,1 Mio. USD, da die Abschreibungen auf immaterielle Vermögenswerte aufgrund beschleunigter Abschreibungen von CDMO-Kundenbeziehungen mehr als verdoppelt wurden (auf 65,4 Mio. USD). Der dem Unternehmen zurechenbare Nettogewinn fiel um 44% auf 52,3 Mio. USD; das verwässerte Ergebnis je Aktie sank von 1,74 auf 1,06 USD.

Segmenttrends:

  • RMS: Umsatz +3,3% auf 213,3 Mio. USD; operative Marge stieg auf 16,8% (+180 Basispunkte).
  • DSA: Umsatz -1,5% auf 618,0 Mio. USD; operative Marge sank um 160 Basispunkte auf 19,9%.
  • Fertigung: Umsatz +4,4% auf 200,8 Mio. USD, aber operatives Ergebnis brach um 68% auf 12,1 Mio. USD ein, hauptsächlich aufgrund höherer Abschreibungen.

Barmittel & Kapital: Der operative Cashflow stieg um 16% auf 376,3 Mio. USD, während die Investitionsausgaben um 20% auf 94,6 Mio. USD zurückgingen, was den freien Cashflow verbesserte. Das Unternehmen kaufte Aktien im Wert von 360,5 Mio. USD (2,1 Mio. Aktien) zurück und verfügt noch über 549,3 Mio. USD unter seiner 1-Milliarde-USD-Autorisierung. Die liquiden Mittel betrugen 182,8 Mio. USD, die Bruttoverschuldung 2,35 Mrd. USD; die Nettoverschuldung stieg leicht an.

Bilanzveränderungen: Der Firmenwert stieg um 89 Mio. USD aufgrund von Wechselkurseffekten; immaterielle Vermögenswerte sanken um 121 Mio. USD durch beschleunigte Abschreibungen. Eigene Aktien im Wert von 363,3 Mio. USD spiegeln die jüngsten Rückkäufe wider.

Sonstige Punkte: Der effektive Steuersatz stieg auf 26,2% (von 21,2%). Restrukturierungskosten beliefen sich im Quartal auf 32,2 Mio. USD. Das Management weist auf weiterhin bestehende Unsicherheiten hin, darunter Lieferkettenprobleme, eine SEC-Untersuchung zur NHP-Beschaffung und mehrere Rechtsstreitigkeiten.

AMERICAN WOODMARK CORP false 0000794619 0000794619 2025-08-05 2025-08-05
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2025

 

 

American Woodmark Corporation

(Exact name of registrant as specified in its charter)

 

 

 

Virginia   000-14798   54-1138147

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification Number)

 

561 Shady Elm Road, Winchester, Virginia   22602
(Address of principal executive offices)   (Zip Code)

(540) 665-9100

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Trading

Symbol

 

Name of Each Exchange

on Which Registered

Common Stock (no par value)   AMWD   NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


American Woodmark Corporation

 

ITEM 1.01

ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

On August 5, 2025, American Woodmark Corporation, a Virginia corporation (“American Woodmark”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with MasterBrand, Inc., a Delaware corporation (“MasterBrand”), and Maple Merger Sub, Inc., a Virginia corporation and wholly owned subsidiary of MasterBrand (“Merger Sub”), providing for Merger Sub, at closing, to merge with and into American Woodmark with American Woodmark surviving as a wholly owned subsidiary of MasterBrand (the “Merger”).

The Board of Directors of American Woodmark (the “Board”) unanimously determined that American Woodmark’s entry into the Merger Agreement, as well as the transactions contemplated by the Merger Agreement, including the Merger, are advisable and in the best interests of American Woodmark and its shareholders. Accordingly, the Board unanimously approved the Merger Agreement, the related plan of merger and the transactions contemplated by the Merger Agreement, including the Merger, and resolved to recommend that American Woodmark’s shareholders vote to adopt the Merger Agreement and approve the Merger and the related plan of merger at a special shareholder meeting to be called by American Woodmark for such purpose. The date, time and location of the special meeting will be announced by American Woodmark.

If the Merger is consummated, American Woodmark’s common stock will be delisted from the NASDAQ Global Select Market and subsequently deregistered under the Securities Exchange Act of 1934, as amended.

Merger Consideration. At the effective time of the Merger (the “Effective Time”), each share of American Woodmark common stock outstanding immediately prior to the Effective Time will be converted into the right to receive 5.150 shares of MasterBrand common stock (such ratio, the “Exchange Ratio”). No fractional shares of MasterBrand common stock will be issued in the Merger. Instead, all fractional shares will be aggregated together and sold on the New York Stock Exchange (“NYSE”) at then-prevailing prices, and any American Woodmark shareholder otherwise entitled to receive fractional shares will be entitled to receive cash in an amount equal to such shareholder’s proportionate interest in the proceeds from the sale of the fractional shares. The Exchange Ratio is subject to adjustment for certain events such as stock splits, reverse stock splits, reclassifications and stock dividends, as and to the extent provided in the Merger Agreement.

Treatment of American Woodmark Equity Awards. Pursuant to the Merger Agreement, as of the Effective Time, each outstanding option to purchase shares of American Woodmark common stock that is outstanding immediately prior to the Effective Time will be assumed by MasterBrand and become a MasterBrand option (i) with respect to a number of shares of MasterBrand common stock equal to the product of the number of shares of American Woodmark common stock subject to the corresponding American Woodmark option (with performance-based vesting conditions determined based upon actual performance through the Effective Time) multiplied by the Exchange Ratio (rounded down to the nearest whole share) and (ii) with a per share exercise price equal to the quotient of the exercise price per share of American Woodmark common stock subject to the corresponding American Woodmark option immediately prior to the Effective Time divided by the Exchange Ratio (rounded up to the nearest whole cent).

The Merger Agreement also provides that, as of the Effective Time, (i) each American Woodmark restricted stock unit (each, an “American Woodmark RSU”) that is outstanding immediately prior to the Effective Time will, depending on the terms of the applicable award, either (1) convert into a MasterBrand restricted stock unit with respect to a corresponding number of shares of MasterBrand common stock based on the Exchange Ratio (with any fractional shares rounded down to the nearest whole share) or (2) convert into the right to receive a number of shares of MasterBrand common stock equal to the number of shares of American Woodmark common stock subject to the American Woodmark RSU immediately prior to the Effective Time multiplied by the Exchange Ratio (with a cash payment in respect of any fractional shares in accordance with the Merger Agreement), less any applicable tax withholding, (ii) each American Woodmark performance stock unit (each, an “American Woodmark PSU”) that is outstanding immediately prior to the Effective Time will convert into a MasterBrand restricted stock unit with respect to a corresponding number of shares of MasterBrand common stock (determined based upon actual or superior performance levels, as applicable) based on the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, and (iii) each American Woodmark cash-settled restricted stock tracking unit outstanding immediately prior to the Effective Time will be assumed and converted into a MasterBrand cash-settled restricted stock tracking unit relating to a corresponding number of shares of MasterBrand common stock (with any


performance-based vesting conditions determined based upon superior performance levels) based on the Exchange Ratio (with any fractional shares rounded down to the nearest whole share). If any American Woodmark option or American Woodmark PSU (to the extent performance-vesting conditions are determined based on actual performance) is not earned based on the achievement of actual performance through the Effective Time, such awards will be automatically cancelled without consideration immediately prior to the Effective Time.

Governance Matters. The Merger Agreement provides that, effective as of the Effective Time, the number of directors that will comprise the board of directors of MasterBrand will be increased to consist of eleven (11) directors, with eight (8) members of the board of directors to be designated by MasterBrand and three (3) members to be designated by American Woodmark. The three (3) members designated by American Woodmark, who will be appointed to fill the vacancies caused by the increase in the size of the board of directors of MasterBrand, must, among other things, meet the independence requirements of NYSE and satisfy MasterBrand’s corporate governance standards, including satisfactory completion of MasterBrand’s customary screening and evaluation procedures for directors. The directors designated by American Woodmark will be assigned to the separate classes of directors of the MasterBrand board of directors as of the Effective Time in accordance with the terms of the Merger Agreement. At the Effective Time, the current Chairman of the MasterBrand board of directors, or such other designee of MasterBrand, will be the Chairman of the MasterBrand board of directors.

The Merger Agreement also provides that, effective as of the Effective Time, MasterBrand’s Chief Executive Officer and President will continue to serve as Chief Executive Officer and President of MasterBrand and that the headquarters of MasterBrand will be the existing headquarters of MasterBrand in Beachwood, Ohio.

Conditions to the Closing of the Merger. Each party’s obligation to close the Merger is subject to the satisfaction or waiver of various conditions specified in the Merger Agreement, including (i) the adoption of the Merger Agreement and approval of the Merger and related plan of merger by the holders of more than two-thirds of the outstanding shares of American Woodmark common stock entitled to vote on such matters (the “American Woodmark Shareholder Approval”), (ii) the approval of the issuance of the shares of MasterBrand common stock to be issued in the Merger by the holders of a majority of the shares of MasterBrand common stock represented and entitled to vote at the stockholder meeting held for such purpose (the “MasterBrand Stockholder Approval”), (iii) the initial and continued effectiveness of a registration statement on Form S-4 to be filed by MasterBrand with the Securities and Exchange Commission in connection with the Merger (the “Registration Statement”), (iv) the listing of the shares of MasterBrand common stock to be issued in the Merger on the New York Stock Exchange, (v) the expiration or termination of the applicable antitrust waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and the receipt of certain other required governmental approvals, (vi) the absence of any injunction or other legal prohibition preventing consummation of the Merger, the issuance of the MasterBrand common stock in the Merger or the other transactions contemplated by the Merger Agreement, (vii) the accuracy of the other party’s representations and warranties, subject to certain materiality thresholds, (viii) the absence of a material adverse effect with respect to the other party, (ix) the receipt of certain certificates and other deliverables, (x) the performance in all material respects by the other party of its pre-closing obligations and covenants under the Merger Agreement, and (xi) in the case of MasterBrand, receipt of a payoff letter indicating the total amount required to be paid to satisfy all amounts outstanding under American Woodmark’s existing credit facility.

Termination of the Merger Agreement. The Merger Agreement may be terminated by the parties in certain circumstances, including through mutual agreement of the parties or by either American Woodmark or MasterBrand unilaterally if (i) the Merger has not closed by 5:00 p.m. Eastern Time on August 5, 2026, subject to certain limited automatic extensions, (ii) the MasterBrand Stockholder Approval is not obtained, (iii) the American Woodmark Shareholder Approval is not obtained, (iv) a final, non-appealable order or other legal restraint is in effect, provided that the terminating party is not primarily responsible for such order or restraint, or (v) the other party breaches its representative, warranties or covenants in a manner that cannot be cured within the time specified in the Merger Agreement. The Merger Agreement may also be terminated (i) by either American Woodmark or MasterBrand if, prior to receipt of the American Woodmark Shareholder Approval, in the case of American Woodmark, or the MasterBrand Stockholder Approval, in the case of MasterBrand, such party’s board of directors authorizes such party to enter into a definitive agreement with respect to a “superior acquisition proposal” as detailed in the Merger Agreement, or (ii) by either American Woodmark or MasterBrand if, prior to receipt of the MasterBrand Stockholder Approval, in the case of American Woodmark, or the American Woodmark Shareholder Approval, in the case of MasterBrand, the other party violates certain non-solicitation provisions in the Merger Agreement or its board of directors changes its voting recommendation to shareholders.


Termination Fees. Upon termination of the Merger Agreement, in certain specified circumstances, including if American Woodmark terminates the Merger Agreement to accept a superior acquisition proposal or violates certain non-solicitation provisions in the Merger Agreement, American Woodmark may be required to pay MasterBrand a termination fee of $25.0 million. Similarly, upon termination of the Merger Agreement, in certain specified circumstances, including if MasterBrand terminates the Merger Agreement to accept a superior acquisition proposal or violates certain non-solicitation provisions in the Merger Agreement, MasterBrand may be required to pay American Woodmark a termination fee of $30.0 million. The Merger Agreement further provides that MasterBrand will be required to pay American Woodmark a reverse termination fee of $35.0 million in the event the Merger Agreement is terminated under certain specified circumstances related to antitrust laws.

Representations, Warranties and Covenants. The Merger Agreement contains certain customary representations and warranties by the parties, as well as certain customary covenants, including regarding the operation of American Woodmark’s and MasterBrand’s respective businesses prior to the Effective Time, each party’s non-solicitation obligations, the efforts of the parties to cause the Merger to be completed, the preparation and filing of the Registration Statement and the obligation of American Woodmark to hold a shareholder meeting to obtain the American Woodmark Shareholder Approval and MasterBrand to hold a stockholder meeting to obtain the MasterBrand Stockholder Approval.

The foregoing descriptions of the Merger Agreement and the transactions contemplated thereby, including the Merger, do not purport to be complete and are subject to, and qualified in their entirety by reference to, the full text of the Merger Agreement, which is filed as Exhibit 2.1 hereto and incorporated herein by reference.

The Merger Agreement has been included as an exhibit hereto solely to provide investors with information regarding its terms. It is not intended to be a source of financial, business or operational information about the American Woodmark, MasterBrand or their respective subsidiaries or affiliates. The representations, warranties and covenants contained in the Merger Agreement were made only for purposes of the Merger Agreement as of the dates specified therein and solely for the benefit of the parties to the Merger Agreement. In addition, the representations, warranties and covenants contained in the Merger Agreement may be subject to qualifications and limitations agreed upon by the parties in connection with negotiating the terms of the Merger Agreement, including being qualified by confidential disclosure schedules made for the purpose of allocating contractual risk among the parties to the Merger Agreement as opposed to establishing such matters as facts, and may further be subject to certain standards of materiality applicable to the contracting parties that differ from those applicable to investors. As a result, investors should not rely on the representations, warranties and covenants included in the Merger Agreement, or any descriptions thereof, as characterizations of the actual state of facts or condition of American Woodmark, MasterBrand or any of their respective affiliates, subsidiaries or businesses. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in American Woodmark’s public disclosures.

 

ITEM 2.02

RESULTS OF OPERATIONS AND FINANCIAL CONDITION

As noted below, on August 6, 2025, American Woodmark and MasterBrand jointly issued a press release announcing the Merger and discussing certain matters related to the Merger. The joint press release includes preliminary net sales, net income and adjusted EBITDA results for American Woodmark for the quarter ended July 31, 2025. A copy of the joint press release is furnished as Exhibit 99.1 hereto and the information under the heading “American Woodmark Q1 Fiscal 2026 Select Preliminary Financial Results,” “Non-GAAP Financial Measures” and “Forward-Looking Statements” is incorporated by reference into this Item 2.02.

 

ITEM 7.01

REGULATION FD DISCLOSURE

On August 6, 2025, American Woodmark and MasterBrand jointly issued a press release announcing the Merger and discussing certain matters related to the Merger. A copy of the press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

In addition, on August 6, 2025, American Woodmark and MasterBrand released a joint investor presentation with respect to the Merger. A copy of the investor presentation is furnished as Exhibit 99.2 hereto and incorporated herein by reference.


ITEM 9.01

FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

 

2.1    Agreement and Plan of Merger, dated as of August 5, 2025, by and among MasterBrand, Inc., Maple Merger Sub, Inc. and American Woodmark Corporation*
99.1    Joint Press Release, dated August 6, 2025
99.2    Joint Investor Presentation, dated August 6, 2025
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
*

Certain schedules and exhibits to Exhibit 2.1 have been omitted as permitted by Item 601 of Regulation S-K

Forward-Looking Statements

Certain statements contained in this report, other than purely historical information, including, but not limited to, statements as to the likelihood and anticipated timing of the closing of the proposed transaction, expected cost synergies and other expected benefits, effects or outcomes relating to the proposed transaction, including financial estimates and projections, MasterBrand’s business plans, objectives and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements preceded by, followed by or that otherwise include the word “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” “may increase,” “may fluctuate,” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. Where, in any forward-looking statement, an expectation or belief is expressed as to future results or events, such expectation or belief is based on the current plans and expectations of the management of MasterBrand or American Woodmark, as applicable. Although MasterBrand and American Woodmark, as applicable, believe that these statements are based on reasonable assumptions, they are subject to numerous factors, risks and uncertainties that could cause actual outcomes and results to be materially different from those indicated or implied in such statements. These factors include a failure by either party or both parties to satisfy one or more of the closing conditions set forth in the merger agreement, including a failure to obtain any required regulatory or governmental approvals or a failure to obtain the required approvals of either American Woodmark’s shareholders or MasterBrand’s stockholders; the occurrence of events or changes in circumstances that give rise to the termination of the merger agreement by either party or a delay in the closing of the transaction; potential litigation relating to the transaction; the effect of the proposed transaction on the ability of either party to retain customers, maintain relationships with suppliers and hire and retain key personnel; the effect of the proposed transaction and the announcement of the proposed transaction on the parties’ stock prices; disruptions in the ordinary course business of either party resulting from the transaction; the continued availability of capital and financing and any rating agency actions related to the transaction or otherwise; the risk that certain limitations in the merger agreement may impact either party’s ability to pursue certain business opportunities or strategic transactions; the diversion of the attention and time of management of either party from ordinary course business operations to the transaction and transaction-related issues; the impact of transaction and/or integration costs and any increases in such costs; the existence of unknown liabilities; the ability of MasterBrand to successfully integrate American Woodmark into its business and operations; and the risk that any anticipated economic benefits, cost savings or other synergies are not fully realized or take longer to realize than expected. Other factors include those listed under “Risk Factors” in Part I, Item 1A of MasterBrand’s Annual Report on Form 10-K for the fiscal year ended December 29, 2024, Part II, Item 1A of MasterBrand’s Quarterly Report on Form 10-Q for the quarterly period ended March 30, 2025, American Woodmark’s Annual Report on Form 10-K for the fiscal year ended April 30, 2025, and other MasterBrand and American Woodmark filings with the SEC.

The forward-looking statements included in this report are made as of the date of this report and, unless legally required, neither MasterBrand nor American Woodmark undertakes any obligation to update, amend or clarify any forward-looking statements to reflect events, new information or circumstances occurring after the date of this report.

Additional Information and Where to Find It

MasterBrand intends to file with the U.S. Securities and Exchange Commission (“SEC”) a registration statement on Form S-4 (the “Registration Statement”), which will include a joint proxy statement of MasterBrand and American


Woodmark that will also constitute a prospectus of MasterBrand. Each of MasterBrand and American Woodmark may also file other relevant documents with the SEC regarding the transaction. This report is not a substitute for the joint proxy statement/prospectus or Registration Statement or any other document that MasterBrand or American Woodmark may file with the SEC. Any definitive joint proxy statement/prospectus (if and when available) will be mailed to shareholders of MasterBrand and American Woodmark. INVESTORS AND SHAREHOLDERS OF MASTERBRAND AND AMERICAN WOODMARK ARE URGED TO READ THE REGISTRATION STATEMENT, JOINT PROXY STATEMENT/PROSPECTUS AND ANY OTHER DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE TRANSACTION, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE, AS THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT MASTERBRAND, AMERICAN WOODMARK, THE TRANSACTION AND RELATED MATTERS. The Registration Statement and joint proxy statement/prospectus and other documents filed by MasterBrand or American Woodmark with the SEC, when filed, will be available free of charge at the SEC’s website at www.sec.gov. Alternatively, investors and shareholders may obtain free copies of documents that are filed or will be filed with the SEC by MasterBrand, including the Registration Statement and the joint proxy statement/prospectus, on MasterBrand’s website at https://masterbrand.com/investors/financials/sec-filings/default.aspx, and may obtain free copies of documents that are filed or will be filed with the SEC by American Woodmark, including the joint proxy statement/prospectus, on American Woodmark’s website at https://americanwoodmark.com/investors/financial-reporting#secfilings. The information included on, or accessible through, MasterBrand’s or American Woodmark’s website is not incorporated by reference into this report.

No Offer or Solicitation

This report is not intended to be and shall not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to appropriate registration or qualification under the securities laws of such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Participants in the Solicitation

MasterBrand, American Woodmark and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the transaction. Information about the directors and executive officers of MasterBrand is set forth in MasterBrand’s proxy statement for its 2025 annual meeting of shareholders, which was filed with the SEC on April 24, 2025, including under the headings “Proposal No. 1 Election of Directors—Our Director Nominees,” “Non-Employee Director Compensation,” “Executive Officers,” “Compensation Discussion and Analysis,” “Stock Ownership Information” and “Equity Compensation Plan Information.” Additional information regarding ownership of MasterBrand securities by its directors and executive officers is included in each person’s beneficial ownership reports on Forms 3, 4 and 5, as filed with the SEC. Information about the directors and executive officers of American Woodmark is set forth in its proxy statement for its 2025 annual meeting of shareholders, which was filed with the SEC on June 25, 2025, including under the headings “Item 1 – Election of Directors—Information Regarding Nominees,” “Executive Compensation,” “Non-Management Directors’ Compensation,” and “Security Ownership,” and in its Annual Report on Form 10-K for the fiscal year ended April 30, 2025, which was filed with the SEC on June 25, 2025, including under the heading “Executive Officers of the Registrant.” Additional information regarding ownership of American Woodmark securities by its directors and executive officers is included in each person’s beneficial ownership reports on Forms 3, 4 and 5, as filed with the SEC. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the definitive joint proxy statement/prospectus included in the Registration Statement, and other relevant materials to be filed with the SEC regarding the transaction when such materials become available. Investors should read the Registration Statement and the joint proxy statement/prospectus carefully if and when these become available before making any voting or investment decisions. You may obtain free copies of these documents from MasterBrand or American Woodmark using the sources indicated above.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AMERICAN WOODMARK CORPORATION

(Registrant)

 

/s/ M. Scott Culbreth

M. Scott Culbreth
President & Chief Executive Officer
Date: August 6, 2025
Signing on behalf of the registrant and as principal executive officer

FAQ

How did CRL’s Q2-25 revenue compare with the prior year?

Total revenue was $1.03 bn, up 0.6% from $1.026 bn in Q2-24, with flat services and 4% higher product sales.

Why did Charles River’s earnings decline in Q2-25?

Profit fell mainly due to a $33 mn YoY increase in intangible amortization and higher SG&A, reducing operating margin.

What happened to the Manufacturing segment’s profitability?

Operating income dropped 68% to $12 mn as CDMO client-relationship intangibles were accelerated for amortization.

How much stock did CRL repurchase and what authorization remains?

CRL bought 2.1 mn shares for $360 mn; $549 mn of the $1 bn program is still available.

What is the status of CRL’s debt and cash balances?

As of June 28 2025, cash was $183 mn; gross debt stood at $2.35 bn, lifting net leverage modestly.

Are there significant legal or regulatory risks disclosed?

Yes. CRL is facing an SEC investigation into its non-human primate supply chain plus several class-action and derivative lawsuits.
Amer Woodmk

NASDAQ:AMWD

AMWD Rankings

AMWD Latest News

AMWD Latest SEC Filings

AMWD Stock Data

787.82M
14.03M
2.04%
104.58%
2.22%
Furnishings, Fixtures & Appliances
Millwood, Veneer, Plywood, & Structural Wood Members
Link
United States
WINCHESTER